AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+0.21%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$251M
AUM Growth
+$251M
(+20%)
Cap. Flow
+$50.5M
Cap. Flow
% of AUM
20.08%
Top 10 Holdings %
Top 10 Hldgs %
47.89%
Holding
91
New
17
Increased
26
Reduced
12
Closed
13
Top Buys
Top Sells
| 1 |
Protagonist Therapeutics
PTGX
|
$6.29M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
$4.33M |
| 3 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$3.38M |
| 4 |
MacroGenics
MGNX
|
$2.15M |
| 5 |
ESSA Pharma
EPIX
|
$2M |
Sector Composition
| 1 | Healthcare | 88.08% |
| 2 | Financials | 6.33% |
| 3 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BridgeBio Pharma
BBIO
$9.89B
| $30.7M | 7.75% | 654,435 +104,435 | +19% | +$4.89M |
|
|
VINC
2
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $16.3M | 4.1% | 1,005,000 +166,689 | +20% | +$2.7M |
|
|
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $15.3M | 3.87% | 270,755 +24,554 | +10% | +$1.39M |
|
|
NARI
4
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $10.9M | 2.77% | 135,000 +50,000 | +59% | +$4.06M |
|
5
Kura Oncology
KURA
$686M
| $9.93M | 2.51% | 530,000 +105,000 | +25% | +$1.97M |
|
|
SWTX
6
DELISTED
SpringWorks Therapeutics
SWTX
| $7.99M | 2.02% | 126,013 +101,013 | +404% | +$6.41M |
|
|
CERE
7
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $7.67M | 1.94% | 259,966 +59,966 | +30% | +$1.77M |
|
8
Ocular Therapeutix
OCUL
$2.12B
| $7.5M | 1.89% | 750,000 +500,000 | +200% | +$5M |
|
|
ARYE
9
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
| $6.94M | 1.75% | +702,500 | New | +$6.94M |
|
10
Aclaris Therapeutics
ACRS
$209M
| $6.3M | 1.59% | 350,000 +75,000 | +27% | +$1.35M |
|
|
XLRN
11
DELISTED
Acceleron Pharma Inc.
XLRN
| $6.08M | 1.54% | 35,350 -19,650 | -36% | -$3.38M |
|
|
ARYD
12
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| $6.04M | 1.52% | 600,000 -100,000 | -14% | -$1.01M |
|
13
Nautilus Biotechnolgy
NAUT
$85.9M
| $5.99M | 1.51% | 975,000 +75,000 | +8% | +$461K |
|
14
Ascendis Pharma
ASND
$11.8B
| $5.72M | 1.45% | 35,910 +15,910 | +80% | +$2.54M |
|
|
15
Zentalis Pharmaceuticals
ZNTL
$122M
| $5.17M | 1.3% | 77,500 -64,918 | -46% | -$4.33M |
|
|
MRTX
16
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $4.87M | 1.23% | +27,500 | New | +$4.87M |
|
17
Travere Therapeutics
TVTX
$1.56B
| $4.85M | 1.22% | +200,000 | New | +$4.85M |
|
18
Curis
CRIS
$20.9M
| $4.5M | 1.14% | 575,000 -75,000 | -12% | -$587K |
|
19
Cytokinetics
CYTK
$4.23B
| $4.47M | 1.13% | 125,000 +55,000 | +79% | +$1.97M |
|
20
Establishment Labs
ESTA
$1.2B
| $4.3M | 1.08% | 60,000 +40,000 | +200% | +$2.86M |
|
21
Iovance Biotherapeutics
IOVA
$807M
| $3.7M | 0.93% | 150,000 +50,000 | +50% | +$1.23M |
|
|
NSTG
22
DELISTED
NanoString Technologies, Inc.
NSTG
| $3.6M | 0.91% | 75,000 +60,000 | +400% | +$2.88M |
|
|
TRIL
23
DELISTED
Trillium Therapeutics Inc.
TRIL
| $3.51M | 0.89% | +200,000 | New | +$3.51M |
|
|
CNTA
24
Centessa Pharmaceuticals
CNTA
$2.25B
| $3.39M | 0.86% | 203,183 +136,226 | +203% | +$2.27M |
|
|
BLU
25
DELISTED
BELLUS Health Inc.
BLU
| $3.27M | 0.83% | 532,030 +232,030 | +77% | +$1.42M |
|